Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Overview
Date Founded

2003

Headquarters

300 THIRD STREET, 3RD FLOOR, CAMBRIDGE, MA, 02142

Type of Company

Public

Employees (Worldwide)

1,323

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Alnylam Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer, Director

President

Senior Vice President, Chief Financial & Accounting Officer

Chief Financial & Accounting Officer

Chief Operating Officer & Executive Vice President

Chief Information Officer & Senior Vice President

Chief Medical Officer

Executive Vice President, Chief Legal Officer & Secretary

Chief Human Resources Officer & Senior Vice President

Vice President, Associate General Counsel

Paths to Alnylam Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Alnylam Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Maverick Capital's investment process is driven by intensive, fundamental bottom-up research. They do not attempt to time the markets or focus on weightings relative to any index. Their research is augmented by a top-down view of individual industries, as well as the efforts of their quantitative research team. The firm's investment team is organized into six industry sector teams: Consumer, Financials, Healthcare, Industrials, Media & Telecom and Technology. The industry sector teams are supported by two discipline research teams: private investments and quantitative. The firm's founder - Lee Ainslie - has ultimate responsibility for all portfolio decisions for Maverick Funds and related Separate Account Clients.

Details Hidden

Manulife AM manages differentiated investment processes and place an emphasis on proprietary fundamental research, but may also employ quantitative analysis. The firm relies on internally generated portfolio analysis, research and proprietary risk metrics. They may also utilize investment advice or research provided by certain US and non-US based affiliated investment advisers. Manulife AM also supplements their internal research with quantitative and fundamental analysis, created primarily by third parties and utilize available sources such as consultants, industry and governmental authorities and experts in related fields. The firm offers investment strategies that extend across a broad range of public and private asset classes, including equity, fixed income, and alternative investments such as oil and gas, real estate, timber and farmland, as well as asset allocation solutions. Their preferred investments strategy seeks to create diversified portfolios of various preferred (including convertible preferred) equity and debt securities. Investments may include securities rated below investment grade and unrated securities, as well as fixed rate and adjustable rate securities and securities issued by foreign issuers.

Details Hidden

FCM seeks to achieve superior risk-adjusted rates of return through a process of fundamental analysis that emphasizes capital preservation. The firm uses the following sources: a variety of publicly available information sources, including but not limited to financial periodicals, corporate rating services, annual reports, prospectuses and filings with the SEC and other regulators, company press releases, as well as, and to the extent applicable or appropriate, information provided by management and creditors of portfolio companies, brokers, dealers, analysts, professional asset managers, research services and hired consultants and advisers. Historically, FCM's core strategies have included merger arbitrage, credit investments, real estate investments, direct investments and long/short equity. They make investments in public and private debt and equity securities, as well as direct investments in private companies and real estate.

Recent Transactions
Details Hidden

Alnylam Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Alnylam Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Alnylam Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Escrow Agent

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Goodwin Procter LLP

Legal Advisor

Chair, Transactional Department at Wilmer Cutler Pickering Hale and Dorr LLP

Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Clients

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Key Stats and Financials As of 2019
Market Capitalization
$15.4B
Total Enterprise Value
$11.4B
Earnings Per Share
$-8.11
EBITDA
$-922M
EBITDAMargin
-419.68%
Enterprise Value Sales
51.66x
Debt TEV
0.03x
TEVNet Income
-12.81x
Total Equity
$1.44B
Total Debt
$304M
Net Profit
$-886M
Revenue
$220M
Five Year Compounded Annual Growth Rate Of Revenue
34.16%
Three Year Compounded Annual Growth Rate Of Revenue
67.03%
Non-Profit Donations & Grants
$2,500 - $4,999
2018
$5,000 - $10K
2017
Investors
Details Hidden

Investor at Alnylam Pharmaceuticals, Inc.

Details Hidden

Cardinal Partners invests in life sciences, medical devices and healthcare information technology. The firm provides financing for early-stage companies with an investment size of $6 million to $12 million. It leads initial round of investment.

Details Hidden

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Suppliers
Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Massachusetts Institute of Technology Hospitals & Patient Services | Cambridge, MA

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Cancer Research UK Other Business & Consulting Services | London, United Kingdom

Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Awards & Honors
2009
World Economic Forum - Technology Pioneers
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alnylam Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alnylam Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Alnylam Pharmaceuticals, Inc..